BTIG Rates ABIVAX Société Anonyme (ABVX) buy, $175 Price Target
BTIG analyst Julian Harrison continues to support ABIVAX with a buy rating and a price target of $175, a 30.17% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated ABIVAX Société Anonyme ($ABVX) "buy" with a $175 price target on June 30, 2026.
Since the rating, $ABVX is up 6.7% after 1 week, down 6.7% after 1 month and down 33.9% to date (from the $133.26 close on Jun 30, 2026).
ABVX
ABIVAX Société Anonyme
Key Points
- On June 30, 2026, BTIG reiterated its Buy rating on ABIVAX (ABVX) with a target price of $175.
- BTIG's $175 price target implies 30.17% upside from ABIVAX Société Anonyme's ($ABVX) current $134.44 share price.
- The stock is currently trading at $134.44, significantly below its 52-week high of $148.83.
- Analysts have a consensus rating of Strong Buy with a mean price target of $163.58.
Get $ABVX trade alerts by text
We text you when insiders, Congress or big funds trade $ABVX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ABIVAX Société Anonyme alert may contain errors. Disclosures
BTIG's Continued Support for ABIVAX
On June 30, 2026, BTIG analyst Julian Harrison reiterated a Buy rating on ABIVAX Société Anonyme (ABVX) on the NasdaqGM, setting a price target of $175. This reflects BTIG's confidence in the company's potential in the biotechnology sector, particularly as it advances its clinical-stage therapeutics.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
BTIG's recent action comes as part of a broader positive sentiment among analysts. On September 22, 2026, Truist Securities maintained its Buy rating with a target of $151, while Wedbush kept a Neutral rating at $118. Barclays also maintained its Overweight rating, with a target of $148. Goldman Sachs initiated coverage with a Buy rating and a target of $155 on September 10, 2026. Overall, analysts have a consensus rating of Strong Buy for ABIVAX, with a mean price target of $163.58, indicating strong confidence in the company’s future performance.
How ABIVAX Société Anonyme Stock Has Traded
As of the last report, ABIVAX shares are trading at $134.44. This price is notably below its 52-week high of $148.83, suggesting potential for growth as the company continues its development efforts. The stock has experienced fluctuations but remains a focus for investors looking at biotech opportunities.
$ABVX price target
ABIVAX Société Anonyme daily closes and this analyst's $175 target. Not advice.
Company Profile
ABIVAX is a clinical-stage biotechnology company based in Paris, France. It specializes in developing therapeutics aimed at stabilizing the immune response in patients suffering from chronic inflammatory diseases. Its lead drug candidate, obefazimod, is currently in Phase 3 clinical development for ulcerative colitis and in Phase 2b trials for Crohn's disease. This focus on innovative treatments positions ABIVAX as a key player in the healthcare sector.
What’s Next for ABIVAX?
Investors will be looking forward to ABIVAX's next earnings report, scheduled for March 22, 2027. The recent analyst ratings and ongoing clinical developments will likely keep the company in the spotlight. Remember, the recent 13F filings reflect past positions and may not represent current ownership stakes.
Related Filing Alerts
Source: BTIG's rating change on $ABVX (Jun 30, 2026). Written by software, not financial advice. How we make alerts